ORPHA:506784
Stevens-Johnson syndrome/toxic epidermal necrolysis overlap syndrome
Also known as: SJS/TEN overlap syndrome · Stevens-Johnson/TEN overlap syndrome · Stevens-Johnson/toxic epidermal necrolysis overlap syndrome
Publications
145
68th percentile
Trials
0
Interventional, condition-specific
Researchers
1,159
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
An intermediate form of Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum characterized by destruction and detachment of the skin epithelium, involving between 10 to 29% of the body surface area, and mucous membranes. Onset usually occurs 4-28 days after administration of the causal medication and is most frequently associated with anticonvulsants, antibacterial sulfonamides, allopurinol, nevirapine, and oxicams (non-steroidal anti-inflammatory drugs), but many other medications have also been implicated. The disease is not induced by medication in 15% of cases. Histology is characterized by an epidermal necrolysis. Multiple disabling long-term sequelae (especially cutaneous, ocular and psychological) are frequent.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0044739
- UMLS:C3661878
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
No specific-condition interventional trial, but broader-category trials exist — discuss eligibility with a clinician.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
145 matched papers (109 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPartial
None under the specific name; 14 for broader category toxic epidermal necrolysis
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
145
145 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
145 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
109 in the last 10 years · high confidence · 68th percentile (publications denominator)
Phrase hits: 145 · MeSH hits: 0
Who's working on it?
1,159
Distinct author names in 145 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Ji C6 papers · 2024
Department of Dermatology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China. jichaofy@fjmu.edu.cn.
Papers in Europe PMC - 02Kim SH6 papers · 2019
Department of Internal Medicine, Eulji University School of Medicine, Daejeon, Korea.
Papers in Europe PMC - 03Gong T4 papers · 2024
Department of Dermatology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
Papers in Europe PMC - 04Chen Y3 papers · 2025
College of Medicine, Chung Shan Medical University Hospital and Chung Shan Medical University, Taichung, Taiwan
Papers in Europe PMC - 05French LE3 papers · 2024
Department of Dermatology and Allergy, University Hospital, Ludwig Maximilian University (LMU) Munich, Munich, Germany. Lars.French@med.uni-muenchen.de.
Papers in Europe PMC - 06
- 07Ingen-Housz-Oro S3 papers · 2024
Dermatology Department, AP-HP, Henri Mondor Hospital, Créteil, France.
Papers in Europe PMC - 08Phillips EJ3 papers · 2022
Division of infectious diseases, Institute of Immunology and Infectious Disease, Murdoch University, Murdoch, Western Australia; Division of Infectious Diseases, Vanderbilt University Medical Center, 1161 21st Avenue South, A-2200, Medical Center North, Nashville, TN 37232-2582, USA. Electronic address: elizabeth.j.phillips@vanderbilt.edu.
Papers in Europe PMC - 09
- 10Satoh TK3 papers · 2024
Department of Dermatology and Allergy, University Hospital, Ludwig Maximilian University (LMU) Munich, Munich, Germany.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present). 14 trials are registered for toxic epidermal necrolysis, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 27 July 2026
No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.
high confidence · 36.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
14 interventional trials matched toxic epidermal necrolysis, the broader category — listed below. Those studies are not counted in the condition-specific total.
Broader category: toxic epidermal necrolysis
14
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT04711200·RECRUITING·LYell SYndrome MEsenchymal Stromal Cells Treatment
Conditions: Epidermal Necrolysis · Lyell Syndrome · Toxic Epidermal Necrolysis · Overlap Syndrome·Matched via name phrase
- NCT06119490·RECRUITING·Evaluation of the Efficacy and Safety of Methylprednisolone Combined With the JAK Inhibitors in the Treatment of Toxic Epidermal Necrolysis
Conditions: Toxic Epidermal Necrolysis·Matched via name phrase
- NCT07110662·NOT YET RECRUITING·New Therapeutic Target for Toxic Epidermal Necrolysis (TEN) Using Anti-CD38+ Monoclonal Antibodies.
Conditions: Toxic Epidermal Necrolysis · Immunotherapy · Cutaneous Adverse Drug Reactions (CADR)·Matched via name phrase
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Stevens-Johnson syndrome/toxic epidermal necrolysis overlap syndrome" OR "SJS/TEN overlap syndrome" OR "Stevens-Johnson/TEN overlap syndrome" OR "Stevens-Johnson/toxic epidermal necrolysis overlap syndrome"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Stevens-Johnson syndrome/toxic epidermal necrolysis overlap syndrome" OR "SJS/TEN overlap syndrome" OR "Stevens-Johnson/TEN overlap syndrome" OR "Stevens-Johnson/toxic epidermal necrolysis overlap syndrome"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"toxic epidermal necrolysis"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T17:55:53.912Z